(Q40667323)

22 September 2017

Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines (English)

1 reference

22 September 2017

1 reference

1 reference

Chad A Ellis

1

1 reference

22 September 2017

Michele D Vos

2

1 reference

22 September 2017

Meredith Wickline

3

1 reference

22 September 2017

Christine Riley

4

1 reference

22 September 2017

Teresa Vallecorsa

5

1 reference

22 September 2017

William G Telford

6

1 reference

22 September 2017

JoAnne Zujewskil

7

1 reference

22 September 2017

Geoffrey J Clark

8

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

Breast Cancer Research and Treatment

22 September 2017

1 reference

22 September 2017

78

1 reference

22 September 2017

1

1 reference

22 September 2017

59-67

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1022105511409

22 September 2017

0 references

cites work

Lipid modifications and function of the ras superfamily of proteins

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

Tissue-specific actions of antioestrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

Altered growth of human colon cancer cell lines disrupted at activated Ki-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Differential expression and mutation of the ras family genes in human breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Aberrant function of the Ras signal transduction pathway in human breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

A farnesyl transferase inhibitor suppresses TPA-mediated skin tumor development without altering hyperplasia in the ras transgenic Tg.AC mouse

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Farnesyltransferase inhibitors: promises and realities

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Tamoxifen and somatostatin affect tumours by inducing apoptosis.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Protein prenylation: more than just glue?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Induction of p21WAF1 expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Biochemical pathways of caspase activation during apoptosis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

The expression of rho proteins decreases with human brain tumor progression: potential tumor markers.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Tamoxifen inhibits acidification in cells independent of the estrogen receptor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1022105511409

7 January 2021

Identifiers

DOI

10.1023/A:1022105511409

1 reference

Dimensions Publication ID

22 September 2017

0 references

1 reference